Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Data: A "Hyperliquid High Success Rate Whale" made an unrealized profit of $241,000 on ETH positions opened yesterday

Data: A "Hyperliquid High Success Rate Whale" made an unrealized profit of $241,000 on ETH positions opened yesterday

ChaincatcherChaincatcher2025/05/14 03:02
Show original

According to ChainCatcher, monitored by on-chain analyst @ai_9684xtpa, the "Hyperliquid high-win-rate whale with over $21.128 million in profits" has an unrealized gain of $241,000 on ETH purchased yesterday (ETH has risen from $2457 to $2649 since then) and has not yet sold.

 
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.